Abstract
BackgroundRheumatoid arthritis (RA) is associated with increased risk of atherosclerotic cardiovascular (CV) disease. Treatment with conventional systemic disease modifying drugs (csDMARDs) such as methotrexate (MTX), as well as biological DMARDs...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have